Advertisement

Topics

Rituximab found to extend progression-free survival in indolent lymphoma

09:30 EDT 26 Mar 2019 | PharmaTimes

New trial results have been published showing that a combination of Celgene's Revlimid and Roche's rituximab significantly extended progression-free survival in patients with relapsed or refractory indolent lymphoma, compared to rituximab with placebo.

Original Article: Rituximab found to extend progression-free survival in indolent lymphoma

NEXT ARTICLE

More From BioPortfolio on "Rituximab found to extend progression-free survival in indolent lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...